Contributors |
|
ix | |
Preface |
|
xi | |
|
History of Pharmacology---From Antiquity to the Twentieth Century |
|
|
1 | (8) |
|
|
1 | (1) |
|
What Is the Position of Pharmacology in the Field of Therapeutics? |
|
|
2 | (1) |
|
The Beginnings of Pharmacology |
|
|
2 | (1) |
|
Pharmacology of the Greco-Roman Era |
|
|
3 | (1) |
|
Pharmacology and the Middle Ages |
|
|
3 | (1) |
|
Pharmacology and the Renaissance |
|
|
4 | (1) |
|
Pharmacology and the Baroque Period |
|
|
5 | (1) |
|
The Birth of Modern Pharmacology |
|
|
5 | (4) |
|
Dosage Forms and Their Routes of Administration |
|
|
9 | (22) |
|
|
9 | (1) |
|
Therapeutic Ramifications in Selecting the Appropriate Dosages Forms |
|
|
10 | (4) |
|
Routes of Drug Administration |
|
|
14 | (17) |
|
Membranes and Drug Action |
|
|
31 | (12) |
|
|
31 | (1) |
|
|
32 | (13) |
|
|
45 | (2) |
|
The Role of Drug Polarity |
|
|
47 | (2) |
|
|
49 | (3) |
|
The Membrane as a Drug Target |
|
|
52 | (4) |
|
|
56 | (1) |
|
Key Points and Conclusion |
|
|
57 | |
|
Ligand-Receptor Binding and Tissue Response |
|
|
43 | (32) |
|
|
63 | (1) |
|
|
63 | (1) |
|
|
64 | (1) |
|
|
64 | (1) |
|
|
65 | (3) |
|
|
68 | (4) |
|
Constitutive Receptor Activity |
|
|
72 | (1) |
|
Extended Ternary Complex Model |
|
|
72 | (1) |
|
|
73 | (2) |
|
Hormesis and Pharmacology |
|
|
75 | (28) |
|
|
75 | (6) |
|
|
81 | (12) |
|
|
93 | (2) |
|
Adaptive Response, Preconditioning and Autoprotection: How These Concepts Relate to Hormesis |
|
|
95 | (1) |
|
Implementing Hormesis into Pharmacology and Toxicology |
|
|
95 | (3) |
|
|
98 | (1) |
|
|
99 | (4) |
|
Signal Transduction and Second Messengers |
|
|
103 | (10) |
|
|
103 | (7) |
|
Receptor/Second Messenger Crosstalk |
|
|
110 | (1) |
|
Signal Transduction Targets for Drug Discovery |
|
|
111 | (2) |
|
|
113 | (18) |
|
|
113 | (1) |
|
|
114 | (8) |
|
Factos Influencing Drug Distribution |
|
|
122 | (2) |
|
Pharmacokinetic/Pharmacodynamic Distribution Properties |
|
|
124 | (1) |
|
|
125 | (2) |
|
|
127 | (4) |
|
|
131 | (44) |
|
|
131 | (6) |
|
Drug-Metabolizing Enzymes |
|
|
137 | (31) |
|
Conclusions and Key Points |
|
|
168 | (7) |
|
|
175 | (26) |
|
|
175 | (1) |
|
Overview of Membrane Transporter Involved in Drug Excretion |
|
|
176 | (5) |
|
|
181 | (13) |
|
Other Routes of Drug Excretion |
|
|
194 | (2) |
|
Drug Excretion: Issues to Consider |
|
|
196 | (1) |
|
Conclusions and Future Perspectives |
|
|
197 | (4) |
|
|
201 | (78) |
|
|
202 | (4) |
|
|
206 | (5) |
|
|
211 | (2) |
|
|
213 | (3) |
|
Elimination (Metabolism and Excretion) |
|
|
216 | (4) |
|
Organization of Single-Dose Pharmacokinetic Model Information |
|
|
220 | (1) |
|
One Compartment Bolus IV Injection (Instantaneous Absorption) Model |
|
|
221 | (6) |
|
One Compartment IV Infusion (Zero-Order Absorption) Model |
|
|
227 | (6) |
|
One Compartment First-Order Absorption Model |
|
|
233 | (7) |
|
Two Compartment Bolus IV Injection (Instantaneous Absorption) Model |
|
|
240 | (8) |
|
Two Compartment IV Infusion (Zero-Order Absorption) Model |
|
|
248 | (5) |
|
Two Compartment First-Order Absorption Model |
|
|
253 | (7) |
|
Generalized Multicompartment Models |
|
|
260 | (4) |
|
|
264 | (7) |
|
Advanced Pharmacokinetic Modeling Topics |
|
|
271 | (5) |
|
|
276 | (3) |
|
Bioanalytical Tools for Drug Analysis |
|
|
279 | (24) |
|
|
279 | (1) |
|
Small Molecule Chemical Bioanalysis |
|
|
280 | (4) |
|
Theoretical Fundamentals of Chromatography |
|
|
284 | (6) |
|
Analytical Separations in Practice |
|
|
290 | (11) |
|
Key Points and Conclusions |
|
|
301 | (2) |
|
Drug-Drug Interactions with an Emphasis on Drug Metabolism and Transport |
|
|
303 | (24) |
|
|
303 | (4) |
|
DDIs Associated with Altered Drug Metabolism |
|
|
307 | (10) |
|
Drug Transporters and DDIs |
|
|
317 | (3) |
|
DDIs Associated with Protein Binding |
|
|
320 | (4) |
|
Conclusions and Key Points |
|
|
324 | (3) |
|
|
327 | (26) |
|
|
327 | (1) |
|
|
327 | (4) |
|
|
331 | (1) |
|
|
332 | (1) |
|
Pharmacovigilance and ADR |
|
|
333 | (1) |
|
|
334 | (15) |
|
|
349 | (4) |
|
|
353 | (18) |
|
|
353 | (1) |
|
|
354 | (1) |
|
|
355 | (1) |
|
|
356 | (1) |
|
|
357 | (7) |
|
Radiological Risk Assessments |
|
|
364 | (1) |
|
|
365 | (2) |
|
|
367 | (4) |
|
|
371 | (16) |
|
|
371 | (1) |
|
Cancer Cell Drug Resistance |
|
|
371 | (8) |
|
Drug Resistance in Infectious Diseases |
|
|
379 | (6) |
|
|
385 | (2) |
|
|
387 | (42) |
|
|
387 | (4) |
|
Ion Channel Structure and Function: Basic Principles and Mechanisms |
|
|
391 | (5) |
|
Ion Channel Pharmacology: Principles and Mechanisms |
|
|
396 | (2) |
|
Ion Channel Groups: Functional Implications and Pharmacological Modulators |
|
|
398 | (16) |
|
Methods for the study of ion channels |
|
|
414 | (6) |
|
|
420 | (1) |
|
Ion Channels as Drug Targets |
|
|
421 | (3) |
|
Key Points and Conclusions |
|
|
424 | (5) |
|
Targeting the Cell Cycle to Kill Cancer Cells |
|
|
429 | (26) |
|
|
429 | (1) |
|
|
429 | (1) |
|
|
430 | (2) |
|
|
432 | (10) |
|
Mitotic Kinases as targets of New Chemotherapeutics |
|
|
442 | (5) |
|
|
447 | (8) |
|
|
455 | (20) |
|
|
455 | (1) |
|
Mechanism and Regulation of PCD |
|
|
456 | (9) |
|
Apoptosis in Health and Disease |
|
|
465 | (2) |
|
Therapeutic Strategies for Targeting Apoptosis |
|
|
467 | (6) |
|
Key Points and Conclusions |
|
|
473 | (2) |
|
|
475 | (86) |
|
|
475 | (10) |
|
|
485 | (47) |
|
Drug Discovery Case Studies |
|
|
532 | (22) |
|
|
554 | (7) |
|
Genomics and Proteomics in Drug Design and Discovery |
|
|
561 | (14) |
|
|
561 | (1) |
|
|
561 | (2) |
|
Major Technological Platforms of Genomics and Proteomics |
|
|
563 | (2) |
|
Current Achievements and Potential Application of Genomics and Proteomics in Drug Design and Discovery |
|
|
565 | (4) |
|
Conclusion and Future Prospects |
|
|
569 | (6) |
|
The Future of Pharmacology |
|
|
575 | (6) |
|
|
575 | (1) |
|
|
575 | (1) |
|
Strategies for Searching for Future Drugs |
|
|
576 | (1) |
|
Tools for Searching for Future Drugs |
|
|
577 | (1) |
|
|
578 | (3) |
Index |
|
581 | |